Short-Term Outcomes of Impella Support in Japanese Patients With Cardiogenic Shock Due to Acute Myocardial Infarction ― Japanese Registry for Percutaneous Ventricular Assist Device (J-PVAD) ―
Authors:
Open Access
- 25 April 2023
- journal article
- research article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 87 (5) , 588-597
Abstract
Background: The Impella®percutaneous left ventricular assist device has been available in Japan since 2017. This is the first large-scale registry study to analyze the efficacy and safety of Impella in Japanese patients with acute myocardial infarction with cardiogenic shock (AMICS).Methods and Results: The Japanese registry for Percutaneous Ventricular Assist Device (J-PVAD) has registered all consecutive Japanese patients treated with Impella. We extracted data for 593 AMICS patients from J-PVAD and analyzed 30-day survival and safety profiles. Overall 30-day survival was 63.1%. The 30-day survival of the Impella alone and Impella plus venoarterial extracorporeal membrane oxygenation (ECPELLA) groups was 80.9% and 45.7%, respectively. The Impella alone group was older and had a lower rate of cardiac arrest, milder consciousness disturbance, less inotrope use, lower serum lactate concentrations, higher B-type natriuretic peptide concentrations, and higher left ventricular ejection fraction (LVEF) than the ECPELLA group. Cox regression analysis revealed that older age and comorbid renal disturbance were common risk factors affecting 30-day mortality in both groups. Major adverse events were hemolysis (10.8%), hemorrhage/hematoma (7.6%), peripheral ischemia (4.4%), stroke (1.3%), and thrombosis (0.7%). LVEF improved in both groups during support.Conclusions: AMICS treatment with Impella showed favorable 30-day survival and safety profiles. The survival rate of patients treated with Impella alone was particularly high. Further studies are needed to improve outcomes of patients with ECPELLA support.Keywords
This publication has 30 references indexed in Scilit:
- Simultaneous Venoarterial Extracorporeal Membrane Oxygenation and Percutaneous Left Ventricular Decompression Therapy with Impella Is Associated with Improved Outcomes in Refractory Cardiogenic ShockASAIO Journal, 2019
- Left ventricular unloading during veno-arterial ECMO: a review of percutaneous and surgical unloading interventionsPerfusion, 2018
- Analysis of outcomes for 15,259 US patients with acute myocardial infarction cardiogenic shock (AMICS) supported with the Impella deviceAmerican Heart Journal, 2018
- Early Initiation of Impella in Acute Myocardial Infarction Complicated by Cardiogenic Shock Improves SurvivalJACC: Cardiovascular Interventions, 2017
- Concomitant Implantation of Impella® on Top of Veno-Arterial Extracorporeal Membrane Oxygenation May Improve Survival of Patients with Cardiogenic ShockEuropean Journal of Heart Failure, 2016
- Characteristics and Predictors of Mortality in Patients With Cardiovascular Shock in Japan – Results From the Japanese Circulation Society Cardiovascular Shock Registry –Circulation Journal, 2016
- Incidence of Hemolysis in Patients with Cardiogenic Shock Treated with Impella Percutaneous Left Ventricular Assist DeviceASAIO Journal, 2016
- A team‐based approach to patients in cardiogenic shockCatheterization and Cardiovascular Interventions, 2015
- Effect of Cardiogenic Shock Hospital Volume on Mortality in Patients With Cardiogenic ShockJournal of the American Heart Association, 2015
- Thirty-Year Trends (1975 to 2005) in the Magnitude of, Management of, and Hospital Death Rates Associated With Cardiogenic Shock in Patients With Acute Myocardial InfarctionCirculation, 2009